OBI-888
- Generic Name
- OBI-888
- Drug Type
- Biotech
- CAS Number
- 2227156-40-1
- Unique Ingredient Identifier
- JI5TBH62QP
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
Phase 1
Terminated
- Conditions
- Metastatic Solid TumorsLocally Advanced Solid Tumors
- Interventions
- Device: Globo H IHC Assay
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT03573544
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath